Daily1d
Lupin bags tentative USFDA nod for Raltegravir Tablets for HIV-1 infection
Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human ...
IPPMEDIA3d
Clinical Trials in South Africa Propel AstraZeneca’s Global Health Research and Capacity
AstraZeneca’s presence in South Africa has become a driving force in global health research, contributing significantly to respiratory, cardiovascular, and oncology therapeutic areas. The ...
The Financial Express3d
USFDA grants tentative approval to Lupin’s generic formulation to treat HIV infection
Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human ...
China Internet Information Center3d
Global medical giants tapping Chinese market at import expo
With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
CC Chemokine Receptor Type 5 Market Research Report 2024
The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...
Xinhua4d
(CIIE) Economic Watch: Global medical giants tapping Chinese market at import expo
"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...
Gilead Sciences Announces Third Quarter 2024 Financial Results
(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...